Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — Investor Presentation (April 2026)
25 slides from Microba Life Sciences's investor presentation, Apr 30, 2026
Slide 1: Q3 FY26 Quarterly Investor Presentation & Webinar
ASX Announcement 30 April 2026 Q3 FY26 Quarterly Investor Presentation & Webinar Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide below its Q3 FY26 Investor Presentation and Investor Webinar with CEO, Dr Luke Reid presenting. Quarterly Investor Webinar Pres
Slide 2: Building the platform for personalised, microbiome-based healthcare
Q3 FY26 Results Building the platform for personalised, microbiome-based healthcare ASX: MAP 30 APRIL 2026 Authorised for release by the Board of Directors 1
Slide 3: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 4: Key Risks & Forward Financial Information Assumptions
Key Risks & Forward Financial Information Assumptions Forward Financial Information Assumptions • Assumes that Operating Expenses, Product Development and Corporate Expenditure grow at a The achievement of the FY26 forward information & ~3-year strategic objectives detailed in slide 4 is rate below
Slide 5: We are building the platform for personalised, microbiome-based healthcare.
“We are building the platform for ~3 Year Strategic Objective personalised, microbiome-based Strong penetration of healthcare.” FY26 innovator & early adopter clinicians. Transformative Expand clinical adoption. patient outcomes across FY25 Break-even in Australia & core regions. United Kingdom1. Br
Slide 6: Q3 FY26 Financial Highlights
Section 1 Q3 FY26 Financial Highlights MICROBA.COM MICROBA LIFE SCIENCES LTD MICROBA.COM EXPECT BETTER © ALL RIGHTS RESERVED EXPECT BETTER
Slide 7: Core Testing Revenues up 99% YoY
Core Testing Global Core Test Volume Revenues up 99% YoY. 6000 5000 4000 Q3 core test volumes up 58% 3000 Annualised run rate of 23,000+ On track for >24,000 FY26 core test volume 2000 and regional break-even guidance 1000 0 Australia United Kingdom Core Testing includes Microbiome Explorer and Meta
Slide 8: Q3 FY26 Business Highlights
Section 2 Q3 FY26 Business Highlights MICROBA.COM MICROBA LIFE SCIENCES LTD MICROBA.COM EXPECT BETTER © ALL RIGHTS RESERVED EXPECT BETTER
Slide 9: Key Highlights
Sub-Section 2.1 Key Highlights 8
Slide 10: Winning key accounts in Australia
Winning key accounts in Australia • In Australia, adoption has now moved beyond innovators into Key Accounts Won early adopters, increasingly characterised by enterprise-style Sales YTD vs Potential 20,000 contracts with healthcare clinics. 18,000 • These accounts when signed and activated, represen
Slide 11: UK Testing Market Outperforming Australia
UK Testing Market Outperforming Australia Post launch regional Post launch test volume, regional comparison • Leveraging the existing comparison – first QTRs – all time acquired customer 900 3500 base in the UK, we are * Full market access *Christmas holiday period impact Full market access continui
Slide 12: New Product Feature Releases
New Product Feature Releases New Test Release Targeting release in Q1 FY27 On track for a major new product release in Q1 FY27. This product is the culmination of several years of leadership at the forefront of this new diagnostic category. This new product represents a meaningful leap in the clinic
Slide 13: New Product Feature Releases
New Product Feature Releases v1.5 Sampling Kit Released for Microbiome Explorer range in February 2026 Better customer experience and lower cost of goods have been delivered via a new Microbiome Explorer sampling Kit (v1.5) across AU and UK, introducing refreshed Microba branding, simplified device
Slide 14: New Product Feature Releases
New Product Feature Releases Clinical Integration Platform Targeted for Q4 FY26 Microba's Clinical Integration Platform embeds our tests into the clinical systems GPs and specialists already use, so they can order, receive results and act on them without leaving their existing practice management so
Slide 15: Diagnostic Results
Sub-Section 2.2 Diagnostic Results 14
Slide 16: Growing Microbiome Explorer sales and clinical adoption in Australia
Growing Microbiome Explorer sales and clinical adoption in Australia Microbiome Explorer Microbiome Explorer Test Sales Volume (AU) Ordering Clinicians (AU) 9,000 1,400 • Record Q3 Microbiome Explorer AU tests 8,245 sales of 4,786 8,000 1,200 1,146 7,000 6,673 1,035 • Q3 Microbiome Explorer AU annua
Slide 17: Strong progress in UK market development for Microbiome Explorer
Strong progress in UK market development for Microbiome Explorer Microbiome Explorer Microbiome Explorer Test Sales Volume (UK) Ordering Clinicians (UK) • Q3 Microbiome Explorer UK test sales of 816 1800 500 • Q3 Microbiome Explorer UK annualised run- 450 1600 1,511 419 rate of ~3,000 tests sold 400
Slide 18: Steady MetaPanel sales and clinical adoption in Australia
Steady MetaPanel sales and clinical adoption in Australia MetaPanel MetaPanel Test Sales Volume (AU) Ordering Clinicians (AU) 600 350 • Steady Q3 MetaPanel test sales of 204 tests 306 500 496 300 • Focus remains on organic development of 276 465 Gastroenterology specialists which will drive 255 250
Slide 19: Supplement Results
Sub-Section 2.3 Supplement Results 18
Slide 20: Supplement growth focused on Invivo branded products
Supplement growth focused on Invivo branded products Supplement Supplement Unit Sales (UK) Revenue (UK) • Invivo branded and owned supplements 70,000 $3,000,000 delivered $0.68m, up 7% vs PCP. 60,000 $2,500,000 • Leading PHGG prebiotic supplement volumes delivered 12,063 units in Q3, up 161% vs 50,0
Slide 21: Therapeutic Partnering
Sub-Section 2.4 Therapeutic Partnering 20
Slide 22: Pipeline of assets backed by big-data, preclinical and clinical validation, targeting deals
Pipeline of assets backed by big-data, preclinical and clinical validation, targeting deals Therapeutic Assets • 5+ years of investment to develop a rich pipeline of live biotherapeutic assets and data, leveraging Microba’s world leading databank generated from it’s testing business • Multiple micro
Slide 23: Focus & Catalysts
Sub-Section 2.5 Focus & Catalysts 22
Slide 24: Key areas of focus & catalysts
Key areas of focus & catalysts Diagnostics Corporate Snapshot • Australia - continued growth in test sales and clinical ASX Code MAP adoption • United Kingdom - continued growth in test sales and Market capitalisation1 $42.62m clinical adoption Shares on issue 608.96m • New test release 52-week low
Slide 25: Contact
Dr Luke Reid Contact Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Chair Laboratory pasquale.rombola@microba.com Princess Alexandra Hospital Woolloongabba QLD Australia 24
Microba Life Sciences — Investor Presentation (April 2026) on 6ix